Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D, Zöller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, Kandler JD, Schneider J, Corman VM, Ciesek S, Rabenau HF, Wass MN, Kippenberger S, Göttig S, Michaelis M, Cinatl J Jr. Bojkova D, et al. Among authors: ciesek s. J Med Virol. 2023 Mar;95(3):e28652. doi: 10.1002/jmv.28652. J Med Virol. 2023. PMID: 36897017
Drug Sensitivity of Currently Circulating Mpox Viruses.
Bojkova D, Bechtel M, Rothenburger T, Steinhorst K, Zöller N, Kippenberger S, Schneider J, Corman VM, Uri H, Wass MN, Knecht G, Khaykin P, Wolf T, Ciesek S, Rabenau HF, Michaelis M, Cinatl J Jr. Bojkova D, et al. Among authors: ciesek s. N Engl J Med. 2023 Jan 19;388(3):279-281. doi: 10.1056/NEJMc2212136. Epub 2022 Dec 28. N Engl J Med. 2023. PMID: 36577096 No abstract available.
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
Koehm M, Klippstein M, Dauth S, Hallmann K, Kohmer N, Burkhardt H, Ciesek S, Geisslinger G, Rabenau HF, Behrens F. Koehm M, et al. Among authors: ciesek s. RMD Open. 2023 Aug;9(3):e003094. doi: 10.1136/rmdopen-2023-003094. RMD Open. 2023. PMID: 37652553 Free PMC article.
Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.
Reus P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, Nordling-David MM, Jbara-Agbaria D, Ciesek S, Bojkova D, Cinatl J, Burger-Kentischer A, Rupp S, Zaliani A, Grunwald T, Gribbon P, Kannt A, Golomb G. Reus P, et al. Among authors: ciesek s. J Control Release. 2023 Dec;364:654-671. doi: 10.1016/j.jconrel.2023.10.050. Epub 2023 Nov 16. J Control Release. 2023. PMID: 37939853 Free article.
221 results